BACKGROUND: Recombinant human lymphotoxin-a derivative (rhLTa-Da) is a lymphotoxin-a derivative that is missing 27 N-terminal amino acid residues. Previous studies indicated a benefit from the addition of rhLTa-Da to cisplatin-based treatment in patients with metastatic esophageal squamous cell carcinoma. The current study was conducted to evaluate the efficacy and safety of rhLTa-Da plus cisplatin and fluorouracil (PF) in patients with mESCC. METHODS: Patients from 15 centers in China were randomly assigned (1:1:1) to 3 arms (arm A, PF plus 10 lg/m 2 daily rhLTa-Da; arm B, PF plus 20 lg/m 2 daily rhLTa-Da; arm C, PF alone). The primary endpoints included progression-free survival (PFS) and the confirmed overall response rate (ORR). An exploratory analysis was performed to evaluate the role of serum tumor necrosis factor receptor II (TNFR II) in predicting the efficacy of rhLTa-Da. RESULTS: Between September 2010 and May 2013, 150 patients were enrolled. No significant differences in either PFS or ORR were observed between the 3 arms. However, in a small subset of patients who had low serum TNFR II levels, the median PFS was significantly longer for those in arm B than for these in other 2 arms (7.2 months [95% confidence interval, 5.1-8. 
INTRODUCTION
Esophageal cancer is the eighth most common malignancy worldwide, and esophageal squamous cell carcinoma (ESCC) accounts for approximately 90% of these cases in China. 1, 2 Platinum, fluorouracil (5-FU), and taxanes are the most commonly used cytotoxic drugs for metastatic ESCC. However, the prognosis for these patients remains poor, with overall response rates (ORRs) of only 23% to 35% and a median overall survival (OS) of 6 to 8 months. 1, [3] [4] [5] [6] Consequently, developing more effective agents to improve the outcome of patients with metastatic ESCC is an urgent need. Lymphotoxin-a (LTa) (also called tumor necrosis factor b [TNFb] ) is a cytokine that is known to mediate not only cytotoxic functions but also a strong antitumor immune response within the intratumoral ectopic lymphoid tissue. 7, 8 It predominantly functions as secreted homotrimers (LTa3), to trigger the transduction of cytotoxic signal through 2 main receptors, TNF receptor I (TNFR I; p55 TNFR) and TNFR II (p75 TNFR). It is reported that TNFR I primarily mediates apoptosis in various tumor cells, 9 whereas the role of TNFR II has not been completely elucidated. It is noteworthy that, when it sheds from the cell surface, the soluble TNFR II can competitively inhibit the interaction of TNF/LT with membrane receptors. Preclinical data indicate that, when combined with chemotherapeutic drugs, particularly platinum, LTa can exert an obvious synergistic cytotoxicity on epithelial cancer cells. [10] [11] [12] However, the instability of LTa in vivo has limited its clinical use.
To exploit the striking tumor-necrotizing activity of LTa, an LTa derivative missing 27 N-terminal amino acid residues, called recombinant human LTa derivative (rhLTa-Da), has been generated to address the aforementioned issues. It is the first LTa derivative to be used in antitumor clinical studies (China patent 97106603; 101073665B). Our preclinical studies have confirmed the comparable bioactivity of rhLTa-Da and LTa. 13 When administered with cisplatin and 5-FU chemotherapy (PF) in a previous phase 2a study, an encouraging response rate of 66.7% was observed in 12 patients with metastatic ESCC, which was much higher than the rate observed with chemotherapy alone in previous reports. [4] [5] [6] 14 On the basis of the promising results from our previous studies, we hypothesized that rhLTa-Da may be effective in the treatment of advanced ESCC. Therefore, in the current phase 2b study, we investigated the activity and safety of rhLTa-Da combined with the standard PF regimen in patients with metastatic ESCC and investigated whether different doses of rhLTa-Da would affect the efficacy and toxicity of the combined regimen. An exploratory analysis was also performed to evaluate the role of serum TNFR II levels in predicting the efficacy of rhLTaDa treatment.
MATERIALS AND METHODS

Patients and Study Design
This prospective, open-label, randomized, controlled, multicenter phase 2b study was conducted at 15 centers in China. Patients ages 18 to 75 years with histologically confirmed, metastatic ESCC were eligible for the study. Prior palliative chemotherapy was not permitted. However, neoadjuvant (adjuvant) or concurrent chemotherapy was allowed, provided that the treatment was completed at least 6 months after chemotherapy (or at least 1 year after chemotherapy if patients had received cisplatinbased or fluorouracil-based regimens as neoadjuvant or adjuvant therapy). Patients were required to meet the following criteria: more than 1 measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 15 ; adequate bone marrow, liver, and kidney functions; a Karnofsky performance status score (KPS) 70; and a life expectancy 3 months.
Patients were excluded for the following reasons: prior neoadjuvant or adjuvant therapy consisting of more than 2 regimens; prior exposure to cisplatin treatment >300 mg/m 2 ; the existence of grade 2 or worse peripheral neuropathy, uncontrolled infection, or complication; a secondary malignancy within the past 5 years (except in situ carcinoma of the cervix or nonmelanoma skin carcinoma); and pregnancy, breastfeeding, or refusal to use contraception.
The study was performed in accordance with good clinical practice guidelines and the Declaration of Helsinki. The trial protocol was approved by the institutional ethics committees at each participating site. All participants signed informed consent before enrollment. This study is registered at chictr.org (no. ChiCTR-TRC-11001197).
Randomization and Masking
Patients were randomly assigned at a ratio of 1:1:1 to 1 of 3 arms (arm A, PF combined with rhLTa-Da 10 lg/m 2 daily; arm B, PF combined with rhLTa-Da 20 lg/m 2 daily; arm C, PF alone). Randomization was stratified by prior treatment (newly diagnosed vs recurrent disease), the number of metastatic sites (3 vs >3 sites), and KPS (<80 vs 80). The random assignment scheme was produced by a computer software program (Drug and Statistics, or Drug Analysis System, version 2.0; Bozhiyin S&T Co. Ltd, Beijing).
Procedures
The study drug rhLTa-Da was provided by FudanZhangjiang Bio-Pharmaceutical Company, Ltd Treatment continued until the completion of 6 cycles, disease progression, intolerable toxicity, or withdrawal of consent. All patients underwent an initial evaluation before randomization, which included a complete medical history, physical examination, complete blood count (CBC), blood chemistry analyses, urine analyses, electrocardiography, and computed tomography or magnetic resonance imaging scans of the relevant region(s). For women, urine pregnancy tests were required before the initiation of treatment. Blood chemistries and complete blood counts were repeated before each cycle of chemotherapy. An imaging study of the relevant region(s) was obtained every 2 cycles during the course of chemotherapy and every 8 weeks after the completion of chemotherapy until patients developed disease progression. Tumor assessments were performed by radiologists in each participating center according to RECIST 1.1 criteria. Adverse events (AEs) and laboratory parameters were recorded throughout the trial and graded according to the National Cancer Institute Common Terminology Criteria (NCI CTC) (version 3.0). Dose modifications (reductions and/or interruptions) after the initiation of rhLTa-Da and/or PF were specified in advance by the trial protocol.
Outcomes
The coprimary endpoints were progression-free survival (PFS) and the confirmed ORR, which was defined as the proportion of patients who a achieved complete or partial response. ORRs were to be confirmed by repeated assessments no less than 4 weeks apart. PFS was defined as the time from randomization to disease progression or death from any cause without prior progression reported. Secondary endpoints included the disease control rate (DCR) (the proportion of patients who were assessed with a complete response, a partial response, or stable disease) and overall survival (OS) (the time from randomization to death from any cause with censoring for patients who remained alive at the study endpoint). The duration of follow-up was defined as the number of days from the time of randomization to the date of death or data cutoff in the absence of death for censored patients. An exploration of predicting the efficacy of rhLTa-Da using the baseline serum TNFR II (p75 TNFR) concentration, a factor that may weaken the effect of TNF/LT by competitive inhibition, also was included in this study.
Serum TNFR II Detection and Cutoff Value Determination
Blood samples for TNFR II detection were collected from all patients before the initiation of treatment using anticoagulant-free tubes. The serum was stored at 2708C until shipment on cold packs to the central laboratory for analysis. Assays for serum TNFR II were conducted using an enzyme-linked immunosorbent assay with a commercially available human TNFR II/TNFRSF 1B Immunoassay (R&D Systems, Minneapolis, MN) according to the manufacturer's recommendations.
The cutoff value for the baseline serologic TNFR II concentration was determined by receiver operating characteristic (ROC) curve analysis. Briefly, the patients in arm B (the high-dose LT plus PF group) were stratified based on their outcome features (PFS >6 months or PFS 6 months). The TNFR II concentration that localized closest to the point of both maximum sensitivity and specificity on the curve was specified as the cutoff value for subsequent subgroup analysis. If the baseline concentration was less than the cutoff, then the patients were classified as TNFR II low; otherwise, they were classified as TNFR II high.
Statistical Analysis
The predicted response rate to the PF regimen in patients with ESCC who were assigned to arm C was 35%, with an approximate median PFS of 4 months. 3, 4 According to the results from our previous phase 2a trials, we estimated that the expected response rate and median PFS for patients who received rhLTa-Da in arm A or B would be approximately 66.7% and 7.6 months, respectively.
14 An accrual time of 24 months was planned along with an additional follow-up of 24 months. An estimated sample size of 150 patients with a 1:1:1 random assignment was required for coprimary endpoints with a 2-sided 5% type I error rate and at least 75% power and 5% loss to follow-up.
Except for the safety analysis, all endpoint analyses were performed in the full analysis set, which included all patients who were randomly assigned to the treatment arms and received at least 1 treatment, but it excluded the eliminated patients. The preprotocol set, which was used for sensitivity analyses of PFS, OS, ORR, and DCR, Original Article comprised patients who met all criteria and had at least 1 response evaluation. Safety was analyzed in the safety set, which included those patients who received at least 1 treatment and had complete records of security indicators. Kaplan-Meier survival curves and the log-rank test were used to detect differences in time-to-event data (PFS and OS) between each group. Binary outcomes (ORR and DCR) were compared using the Cochran-MantelHaenszel chi-square test. Other categorical variables were analyzed with the Pearson chi-square test and the Fisher exact test. All statistical analyses were conducted at 5% significance with a statistical analysis system (SAS version 9.2; SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
From December 2010 to May 2013, 150 patients were enrolled at 15 centers in China. The CONSORT diagram is provided in Figure 1 . The full analysis set included 143 patients (arm A, n 5 48; arm B, n 5 47; arm C, n 5 48), the safety analysis set included 145 patients, and the perprotocol set included 122 patients. At the cutoff time (June 2015), 132 of 143 patients had experienced disease progression or died. Demographics and baseline characteristics of the patients were generally well balanced among the 3 treatment groups (Table 1) . Although the serum TNFR II level was not defined as a stratification factor in the protocol, the patients with low and high TNFR II levels were distributed equally in each arm.
Treatment Exposure
The median number of cycles of the protocol-specified treatment was 4 for each of the 3 groups. More than onehalf patients received 4 treatment cycles, with 31.3% of patients in arm A, 21.3% of those in arm B, and 22.9% of those in arm C receiving 6 cycles.
The proportion of patients who received postprogression treatment was similar in each arm. The types of treatments received also were similar in each arm (subsequent chemotherapy, 45.8%, 34%, and 54.2% in arms A, B, and C, respectively; palliative radiotherapy, 20.8%, 19.1%, and 27.1%, respectively; and stent implantation, 2.1%, 0%, and 8.5%, respectively). 
Efficacy
Neither low-dose rhLTa-Da (arm A) nor high-dose rhLTa-Da (arm B) plus chemotherapy induced a statistically significant improvement in PFS compared with chemotherapy alone (arm C). For arms A, B, and C, the median PFS was 3.9 months (95% confidence interval [CI], 2.9-5.3 months), 5.7 months (95% CI, 3.2-6.8 months), and 4.9 months (95% CI, 3.1-6.1 months), respectively. A Cox multiple regression model revealed no significant differences between arms A and C (hazard ratio, 1.238; 95% CI, 0.769-1.994; P 5 .380) or between arms B and C (hazard ratio, 0.837; 95% CI, 0.517-1.354; P 5 .468) (Fig. 2A) . The ORR and DCR were higher numerically, but not statistically, for arm B than for arm A or C (ORR: arm A, 27.1%; arm B, 46.8%; arm C, 41.7%; P 5 .073; DCR: arm A, 64.6%; arm B, 76.6%; arm C, 75%; P 5 .203) ( Table 2 ). There also were no statistically significant differences between the 3 treatment (Fig. 2B ). Table 3 lists the most commonly reported AEs regardless of their positive relation to treatment. Myelosuppression, fatigue, nausea, anorexia, and vomiting were the most frequently reported AEs in all 3 groups. Patients assigned to arm A or B had higher incidence rates of chills, fever, hypertension, anemia, and neutropenia than patients assigned to arm C. Although most of these differences in the incidence of toxicity did not reach statistical significance, the incidence rates of chills increased significantly in the experimental groups (arm A, 32.7%; arm B, 47.9%; arm C, 0%; P < .001). The proportions of patients among different groups who reported NCI CTC ; arm C, 6.3%; P 5 1.0). These fatal SAEs were considered to be related to tumor progression. There were no drug-related deaths during the study. All SAEs in arms A and B were considered unrelated to rhLTa-Da.
Safety
Serum TNFR II Concentration
Baseline serum TNFR II was detected for 140 of 143 patients (97.9%) in the full analysis set population, for 119 of 122 patients (97.5%) in the preprotocol set population, and in 142 of 145 patients (97.9%) in the safety set population. For the whole population that had TNFR II detected (n 5 142), the median of TNFR II level was 2873.5 pg/ml (rang: 1387-9057 pg/ml). A cutoff of 2231 pg/ml was determined by the ROC curve analysis, as described above (see Materials and Methods and Supporting Fig. 1 ; see online supporting information). Patients who had serum TNFR II concentrations below 2231 pg/ ml were classified as TNFR II low (28 patients), and all others were classified as TNFR II high (112 patients).
In the TNFR II-low population, patients who received high-dose rhLTa-Da in addition to PF chemotherapy had a statistically significant improvement in PFS compared with the other 2 groups (median PFS: arm A, 3.5 months [95% CI, 1.7-5. (Fig. 3A) , although only a numeric benefit was observed in the experimental groups for response rates (ORR: arm A, 16.7%; arm B, 77.8%; arm C, 38.5%; P 5 .722; DCR: arm A, 50%; arm B, 100%; arm C, 84.6%; P 5 .165) (Supporting Table 1 ; Table 2 ; see online supporting information), probably because of the small sample size in the subset and the disturbance in subsequent therapy. However, in the TNFR II-high population, no significant differences in PFS were observed among the 3 treatment arms (median PFS: arm A, 4.0 months [95% CI, 2.4-5.3 months]; arm B, 3.8 months [95% CI, 3.0-6.7 months]; arm C, 4.9 months [95% CI, 3.0-6.6 months]; P 5 .707) (Fig. 3A) ; likewise, there no differences were observed in the response rates or in OS (Supporting Tables 1 and 2 ; see online supporting information). In addition, in both the low and high TNFR II populations, the addition of rhLTa-Da significantly increased the incidence of chills (TNFR II-low subset: arm A, 33.3%; arm B, 33.3%; arm C, 0%; P 5 .033; TNFR II-high subset: arm A, 34.1%; arm B, 51.3%; arm C, 0%; P < .001) (Supporting Table 3 ; see online supporting information). However, no significant difference in the incidence of rhLTa-Da2related toxicity (like chills, fever, and hypertension) was observed between the low and high TNFR II populations in the patients who received rhLTa-Da combined therapies.
DISCUSSION
The current randomized phase 2b trial indicated that rhLTa-Da, when combined with PF chemotherapy, failed to improve the PFS or ORR of patients with metastatic ESCC in the general population, despite a trend toward improvement in response to high-dose rhLTa-Da. A previous preclinical study demonstrated that platinum enhanced the efficacy of LTa against human epithelial tumor cells by a mechanism of platinum-induced suppression of nuclear factor-kappaB (NFjB) and subsequent down-regulation of X-linked inhibitor of apoptosis protein (XIAP). 10 In an additional pilot, phase 2a trial, the combined rhLTa-Da and PF regimen induced a superior response rate (66.7%) in 12 patients with metastatic ESCC compared with PF alone (range, 23%-35%) in previous studies. [4] [5] [6] 14 However, rhLTa-Da failed to produce an obvious beneficial effect in the current study, which expanded the sample size. The numerically (but not statistically) superior outcome of the high-dose rhLTa-Da group suggested the complexity of the inflammatory microenvironment in cancer and the challenge of immunotherapy.
In further exploratory analyses, the addition of highdose rhLTa-Da to chemotherapy significantly prolonged PFS in a small subgroup with low serum TNFR II levels, as opposed to those with high TNFR II levels. This finding was consistent with prior literature indicating that the shed decoy portion of TNF/LT receptors, including the detected serum-soluble TNFR II receptor, served as a native antagonist of TNF/LT by interfering with the binding between TNF/LT and membrane receptors. [16] [17] [18] [19] That is, high serum levels of TNF receptors may weaken the cytotoxic effect of rhLTa-Da by nonfunctionally binding to the majority of rhLTa-Da, resulting in a low drug concentration in the tumor tissue; whereas a low concentration of serum TNFR II receptors can ensure an effective concentration of rhLTa-Da in tumor tissue and the subsequent receptor ligation to the membrane. A higher dosage of rhLTa-Da or a newly reconstructed LT derivative that can only target the membrane receptor without the combination with serum-soluble receptor has the potential to improve efficacy in the high TNFR population. Despite all of this, the small sample size, especially for the low TNFR II population, weakens the credibility of the exploratory results, which should be interpreted with caution. Differences in the incidence of grade 3 or higher AEs, AEs leading to treatment interruptions, SAEs, and fatal SAEs among the 3 treatment groups did not reach statistical significance. Patients in all 3 groups tolerated their treatments well. The reported AEs, including anemia, neutropenia, leucopenia, thrombopenia, constipation, diarrhea, nausea, vomiting, poor appetite, stomatitis, and fatigue, were primarily attributed to the PF regimen. The LT-related AEs included chills, hypertension, and fever. These were consistent with the theory that, as a derivative of LTa, rhLTa-Da has proinflammatory side effects similar to TNFa, which are primarily associated with pyrexia, chills, rigors, and hypertension after systemic application. [20] [21] [22] In our previous phase 1 trial, grade 1 through 3 chills and fever were observed in 79.2% patients. 23 To better control for the acute AEs of rhLTa-Da, pretreatment with the cyclooxygenase inhibitor indomethacin was used in our current phase 2b trial. 24, 25 This pretreatment dramatically decreased both the degree and incidence of rhLTa-Da-related AEs, which facilitated the systematic administration of rhLTa-Da in clinical practice.
Overall, our phase 2b study failed to meet the primary endpoints of significant PFS and ORR benefits with combined rhLTa-Da and PF chemotherapy compared with chemotherapy alone in patients with metastatic ESCC. However, in a small subgroup of patients with low baseline TNFR II concentrations, prolonged PFS with combined therapy probably indicated a role for the serum TNFR II concentration in predicting the efficacy of rhLTa-Da. However, considering the small patient numbers, the results still should be interpreted with caution. New derivatives that can only target membrane receptors without the interference of serum receptors could be the future research direction for antitumor reconstructed LT.
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